Overview

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Status:
Enrolling by invitation
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Phase:
Phase 3
Details
Lead Sponsor:
United Therapeutics